ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access
Balamurali Venkatesan1 , Leela Kakithakara Vajravelu1, Sujith Ravi1, Jayaprakash Thulukanam1 and Om Lokesh Muthamilan2
1Department of Microbiology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu District, Tamilnadu, India.
2Department of Microbiology, Kasturba Medical College, 203, Light House Hill Road, Hampankatta, Mangalore, Karnataka, India.
Article Number: 8398 | © The Author(s). 2023
J Pure Appl Microbiol. 2023;17(1):395-402. https://doi.org/10.22207/JPAM.17.1.30
Received: 02 January 2023 | Accepted: 13 February 2023 | Published online: 01 March 2023
Issue online: March 2023
Abstract

The pandemic on SARS-CoV-2 infection has adversely impacted mankind all over the globe and more importantly, amidst individuals having Type-2 diabetic mellitus (T2DM) as well as among those who produce SARS-CoV-2 intricacies. Humoral and T cell-mediated immunity are adaptive immunity has a pivotal role to play in removing pathogens, comprising SARS-CoV-2. The infected cells are being eliminated by the primarily cytotoxic CD8+ T cells as well as certain antibodies in opposition to SARS-CoV-2 among humoral immunological responses possess the capacity for neutralizing this virus or by eliminating the infected cells with the support of cytotoxic in order to manage the progression of the disease. This cross-sectional study was carried out between January 2022 to December 2022. The serum samples were used to analyze SARS-CoV-2 total Ab among individuals having and not having T2DM and several metabolic risk factors like hypertension using WANTAI SARS-CoV-2 Total Ab ELISA Kit. There were 354 individuals, of which 141 (39.8%) had T2DM and 213 (60.2%) were nondiabetic patients. T2DM showed reduced antibody levels (average 5 AU/ml) than those without diabetes (average 12 AU/ml). SARS-CoV2 total antibody levels are considerably lower in hypertension patients (8 AU/ml) over those who are normotensive (14 AU/ml). The present study implies that the continuous monitoring of the total antibody profile of SARS-CoV-2 that may be a practical strategy to help individuals with T2DM and hypertension to determine their need of precautionary doses for sustaining SARS-CoV-2 vaccines by producing immunity for protection against infections.

Keywords

SARS-CoV-2 Vaccines, Diabetic, Non-diabetic, Comorbidities, SARS-CoV-2 Total Antibody Levels

Article Metrics

Article View: 877

Share This Article

© The Author(s) 2023. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.